Table 2

Results relating to clinical change and study attrition.

Months

Number of trials

Chlorpromazine

Placebo

RR (95% CI)

Test for heterogeneity


events/total participants


Relapse

6–24

3

108/202

159/192

0.65 (0.5–9.0)

Chi2 7.83, df 2, p = 0.02 I2 = 74.5%*

No global improvement

2–6

13

470/654

406/467

0.76 (0.7–0.9)

Chi2 25.4, df 12, p = 0.01 I2 = 52.8%

Leaving the study early

6–24

2

38/254

33/238

1.09 (0.7–1.6)

Chi2 0.47, df 1, p = 0.49 I2 = 0%


* no clear cause of heterogeneity found on close re-inspection of trials

Adams et al. BMC Medicine 2005 3:15   doi:10.1186/1741-7015-3-15

Open Data